CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates

Group 1 - CRISPR Therapeutics AG reported a quarterly loss of $0.44 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.15, representing an earnings surprise of 61.74% [1] - The company posted revenues of $35.69 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 252.50%, although this is a decline from $201.21 million in the same quarter last year [2] - Over the last four quarters, CRISPR Therapeutics has surpassed consensus EPS estimates three times, indicating a mixed performance trend [2][6] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$1.43 on revenues of $8.09 million, and for the current fiscal year, it is -$5.25 on revenues of $155.74 million [7] - The Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]